NIKKEI 225
38,471.20 -761.60 (-1.94%) HANG SENG
16,248.97 -351.49 (-2.12%) CRUDE OIL
85.45 +0.04 (+0.05%) GOLD FUTURES
2,411.60 +28.60 (+1.20%) DOW
37,865.29 +130.18 (+0.34%) Bitcoin GBP
50,225.38 -1,408.22 (-2.73%)
Roche Holding AG (RHHBY)
| Previous close | 30.58 |
| Open | 30.31 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 30.15 - 30.34 |
| 52-week range | 30.06 - 40.48 |
| Volume | |
| Avg. volume | 2,260,690 |
| Market cap | 196.069B |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | 15.42 |
| EPS (TTM) | 1.96 |
| Earnings date | N/A |
| Forward dividend & yield | 1.39 (4.55%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 38.19 |
ZacksAdaptimmune (ADAP) Down on End of Collaboration With Roche
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
ZacksRoche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
Business WireGenentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
SOUTH SAN FRANCISCO, Calif., April 15, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, lived longer when treated with Columvi® (glofitamab-gxbm) in combination wi
